Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab for RVO in Japan
NCT01377597Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2011
- Primary completion
- Apr 2012
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ranibizumab in macular edema, sponsored by Novartis. Primary endpoint: Mean average change in best-corrected visual acuity (BCVA) from Month 1 through Month 3 compared to baseline. Started Jun 2011; status: completed.
02
Drugs
ranibizumab
03
Conditions
macular edema
Beyond the preview
Go deeper on NCT01377597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01377597.